Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Insmed has strong biotech catalysts: Q2 revenue was $425.5M, BRINSUPRI revenue grew 49% sequentially to $309.2M, 2026 BRINSUPRI guidance was raised to $1.25B-$1.40B, TPIP data were favorable, and the Q2 loss of $0.52 beat the $0.69 consensus loss.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Negative cash flow ⢠High valuation INSM's improving revenue, margins, EBITDA, and liquidity are offset by persistent cash burn, leverage, accumulated losses, and an expensive valuation.
Price Behavior
Key Price Behavior Insights: ⢠Support defended ⢠Resistance stalled ⢠Breakout needed Support Level: $121.39â$121.82; deeper support at $118.54 Resistance Level: $126.63â$126.68 INSM rebounded from $118.54 support but remains below $126.63â$126.68 resistance over the last month, so wait for a breakout before turning bullish.
Sentiment & News
Key News Insights: ⢠Raised BRINSUPRI Guidance ⢠Japan Market Approval ⢠Narrower Quarterly Loss Insmed's strong BRINSUPRI-led growth, raised guidance, narrowed losses, and Japan approval reinforce a positive commercial outlook despite ongoing unprofitability.
AI Summary
INSM is transitioning into a commercial respiratory platform as BRINSUPRI's rapid growth builds a potential self-funding base, but at ~25x sales investors should wait for sustained adoption and positive free-cash-flow conversion before underwriting further upside.
Description
Insmed is a biopharmaceutical company that develops and commercializes therapies for patients with serious and rare diseases, and it markets ARIKAYCE for adult Mycobacterium avium complex lung disease as part of a combination antibacterial regimen. The companyâs pipeline includes Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor in development for bronchiectasis and other neutrophil-mediated conditions, and an inhaled treprostinil palmitil prodrug being studied for pulmonary arterial hypertension and other rare pulmonary disorders.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 7 | Aug 14 | INSM | Insmed Incorporated | Insmed has strong biotech catalysts: Q2 revenue was $425.5M, BRINSUPRI revenue grew 49% sequentially to $309.2M, 2026 BRINSUPRI guidance was raised to $1.25B-$1.40B, TPIP data were favorable, and the Q2 loss of $0.52 beat the $0.69 consensus loss. | Closed | -5.6% |
| Jul 8 | Jul 15 | INSM | Insmed Incorporated | Strong healthcare momentum with concrete clinical and commercial support: shares rose 22.7% over 21 trading days, Q1 2026 revenue was $306.0M, ENCORE met its primary and key secondary endpoints, and pipeline activity includes TPIP Phase 3 initiation. | Closed | -5.8% |
| Apr 1 | Apr 8 | INSM | Insmed Incorporated | Fresh positive Phase 3 ENCORE topline (3/23) and strong 2026 revenue guidance (BRINSUPRI âĽ$1B, ARIKAYCE $450â470M) have driven ~9.8% 21-day ROC and price ~13% above the 21-day SMA. With Phase 2b CEDAR topline due in Q2 2026, the stock is a high-risk but well-defined event-driven long for the coming days. | Closed | -2.8% |
| Nov 24 | Dec 1 | INSM | Insmed Incorporated | Insmed (INSM) is supported by FDA approvals, strong Q3 revenue growth (+22% ARIKAYCEÂŽ), bullish technical momentum (+24.5% over 21 days), and raised guidance reflecting commercial traction. Despite continuing losses and high valuation, ongoing pipeline catalysts and significant liquidity underpin a moderate short-term upside case. | Closed | +2.2% |